$HRC (Hill-Rom Holdings, Inc.)

$HRC {{ '2016-06-16T16:29:27+0000' | timeago}} • Announcement

Medical technology company $HRC said that it unveiled the VisiVest System, a connected therapeutic solution for patients in need of airway clearance therapy. This is the world's first solution that combines high-frequency chest-wall oscillation (HFCWO) technology with wireless connectivity powered by Qualcomm Life, Inc., a subsidiary of $QCOM.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$HLS {{ '2017-12-12T13:23:46+0000' | timeago}} • Announcement

$HLS appointed Nancy Schlichting as an independent director, effective Dec. 11, 2017. With this appointment, the Board will expand to 11 directors. Schlichting currently serves on the boards of $WBA and $HRC.

$HRC {{ '2017-11-27T15:52:09+0000' | timeago}} • Announcement

IMRIS and $HRC said Hill-Rom's Trumpf Medical has completed device listing and registration with FDA for a new multi-functional operating room table specifically designed for the IMRIS Surgical Theatre. Full market launch is expected in early 2018.

$HRC {{ '2017-10-11T12:47:11+0000' | timeago}} • Announcement

$HRC provided an update on its Aspen Surgical facility in Las Piedras, Puerto Rico, where the company manufactures Bard-Parker surgical scalpels and blades. The company confirmed that the facility sustained minor structural damage, temporary loss of power and minimal water damage due to Hurricane Maria.

$HRC {{ '2017-10-10T14:13:09+0000' | timeago}} • Announcement

$HRC's Welch Allyn subsidiary said its home medical devices will now be offered as part of $HON’s remote patient monitoring platform. The Welch Allyn Home 1700 Series Blood Pressure Monitor and Welch Allyn Home Weight Scale will be offered as standard peripherals with Honeywell Life Care Solution's Genesis Touch remote patient monitoring kits.

$HRC {{ '2017-10-05T12:06:47+0000' | timeago}} • Announcement

Chairman of $HRC Board Rolf Classon will not stand for re-election to the BoD when his current term expires on March 6, 2018. The Board plans to appoint current independent director William Dempsey to this role if he is re-elected by shareholders. The company also elected Gary Ellis, retired CFO and SVP of $MDT, to its BoD, effective Oct 5, 2017.

$HRC {{ '2017-07-19T14:11:03+0000' | timeago}} • Announcement

$HRC declared a dividend of $0.18 per share for 4Q17 payable on September 29, 2017, to shareholders of record as of September 15, 2017. The indicated annual dividend rate is $0.72 per share.

$HRC {{ '2017-05-26T13:49:04+0000' | timeago}} • Announcement

$HRC's BoD declared 3Q17 dividend of $0.18 per share. The dividend is payable on June 30, 2017, to shareholders of record on June 16, 2017. The indicated annual dividend rate is $0.72 per share.

$HRC {{ '2017-03-14T20:28:28+0000' | timeago}} • Announcement

$HRC's BoD declared a 6% increase in its quarterly dividend rate to $0.18 per share. The FY17 quarterly dividend is payable on March 31, 2017, to shareholders of record on March 24, 2017. The indicated annual dividend rate is $0.72 per share. $HRC also elected Mary Garrett and Nancy M. Schlichting as new members of its BoD.

$HRC {{ '2017-02-15T13:41:14+0000' | timeago}} • Announcement

$HRC completed the acquisition of Mortara Instrument, Inc., for $330MM in cash. The transaction was financed through a private offering of $300MM of senior unsecured notes. The acquisition accelerates the company's revenue growth, and is accretive to adjusted gross and operating margins, and is immediately accretive to $HRC FY17 adjusted earnings.

$HRC {{ '2017-02-09T19:49:02+0000' | timeago}} • Announcement

$HRC announced the planned private offering of $300MM of senior unsecured notes due 2025. The Notes will be guaranteed on a senior unsecured basis by certain of $HRC's existing and future wholly‑owned domestic restricted subsidiaries.

$HRC {{ '2017-01-27T19:03:53+0000' | timeago}} • Webcast

$HRC stated that its US orders in 1Q17 rose 4%, while the backlog increased 7% vs. the year ago quarter after adjusting for divested businesses. Importantly, U.S. performance continues to be strong driven by strong growth of higher margin products, including Clinical Workflow Solutions, specialty frames and patient handling and service offerings.

$HRC {{ '2017-01-27T19:02:54+0000' | timeago}} • Webcast

On a segment basis, $HRC’s Domestic revenue, which accounts for almost 75% of the total business, grew 3% despite a difficult comparison with a large customer order from last year and lower revenue from divested businesses. Collectively, U.S. growth was impacted by more than 200 BP due to these factors.

$HRC {{ '2017-01-27T19:01:03+0000' | timeago}} • Webcast

$HRC said its revenue outside the U.S. was lower than the prior year. However, looking forward the company expects international performance to return to growth beginning in 2Q17, driven by improvements in several key geographies.

$HRC {{ '2017-01-27T18:59:14+0000' | timeago}} • Webcast

$HRC saw momentum in its Surgical Solutions business in 1Q17 with double-digit growth in the US, while Front Line Care performance was offset by the change in Welch Allyn’s fiscal year & distributor order timing. With consistent end user demand growth, $HRC's full year revenue expectation for Front Line Care continues to be mid single-digit growth.

$HRC {{ '2017-01-27T12:31:21+0000' | timeago}} • Announcement

For 2Q17, $HRC expects revenue to increase 2-3%.  Excluding the impact of completed or potential divestitures, $HRC’s core revenue is expected to increase 4-5% on a constant currency basis. $HRC also expects adjusted diluted EPS, excluding special items, of $0.77-0.79.

$HRC {{ '2017-01-27T12:29:24+0000' | timeago}} • Announcement

For full-year 2017, $HRC expects revenue to increase approx. 1%. Excluding the impact of completed and potential divestitures, $HRC’s core revenue is expected to increase 3-4% on a constant currency basis. The company expects adjusted EPS of $3.74-3.82 and $330-340MM in operating cash flow.

$HRC {{ '2017-01-27T12:25:49+0000' | timeago}} • Announcement

In 1Q17, $HRC’s Patient Support Systems segment revenue was $335MM, down 2% from 1Q16. Front Line Care, which includes Welch Allyn and Respiratory Care, generated revenue of $202MM, a decline of 8%. Surgical Solutions revenue was $100MM, up 1% from last year.

$HRC {{ '2017-01-27T12:22:41+0000' | timeago}} • Announcement

Medical technology company $HRC reported an increase in 1Q17 earnings. Net income was $23.8MM or $0.36 per share compared to $4.8MM or $0.07 per share in 1Q16. Adjusted EPS was $0.75, up 10% from the prior-year period. Worldwide revenue of $637MM declined 4% compared to last year. On a constant currency basis, revenue declined 3%.

$HRC {{ '2017-01-10T13:26:52+0000' | timeago}} • Announcement

$HRC agreed to buy privately-held Mortara Instrument. The acquisition is expected to accelerate $HRC's revenue growth and be accretive to both gross and operating margins. Excluding special items. the transaction is expected to be modestly accretive to $HRC's FY17 adjusted EPS. $HRC plans to realize annual operational synergies of at least $10MM.

Recent Transcripts

CMD (Cantel Medical Corp.)
Thursday, December 7 2017 - 4:00pm
MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
GMED (Globus Medical, Inc.)
Wednesday, November 8 2017 - 10:30pm
SRCL (Stericycle, Inc.)
Wednesday, November 8 2017 - 10:01pm
HOLX (Hologic Inc.)
Wednesday, November 8 2017 - 9:30pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
TFX (Teleflex Incorporated)
Thursday, November 2 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
SYK (Stryker Corporation)
Thursday, October 26 2017 - 8:30pm
RMD (ResMed Inc.)
Thursday, October 26 2017 - 8:30pm
BABY (Natus Medical Inc.)
Wednesday, October 25 2017 - 3:00pm
GE (General Electric Company)
Friday, October 20 2017 - 12:30pm
ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
JNJ (Johnson & Johnson)
Tuesday, October 17 2017 - 12:30pm

AlphaGraphics you may like